Home » Stocks » ELOX

Eloxx Pharmaceuticals, Inc. (ELOX)

Stock Price: $2.54 USD -0.22 (-7.97%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 121.44M
Revenue (ttm) n/a
Net Income (ttm) -34.58M
Shares Out 40.12M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $2.54
Previous Close $2.76
Change ($) -0.22
Change (%) -7.97%
Day's Open 2.78
Day's Range 2.52 - 2.78
Day's Volume 68,020
52-Week Range 1.98 - 6.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) has acquired Zikani Therapeutics Inc in an all-stock transaction. The new entity will focus on ribosomal RNA-targeted therapies for the treatment of rare disease...

2 weeks ago - Benzinga

Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms

2 weeks ago - GlobeNewsWire

We expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of this year

1 month ago - GlobeNewsWire

Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET Company management to host a webcast and conference call to provide a b...

1 month ago - GlobeNewsWire

Publication titled: “ A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects”

2 months ago - GlobeNewsWire

Publication titled: “Phase 1 Renal Impairment Trial Results Enable Targeted Individualized Dosing of ELX-02 in Nephropathic Cystinosis Patients” Publication titled: “Phase 1 Renal Impairment Trial Resul...

2 months ago - GlobeNewsWire

The CF Foundation's partial funding of the U.S. trial has been extended to partial funding of the global clinical trial program which includes Europe and Israel

3 months ago - GlobeNewsWire

Eloxx Pharmaceuticals (ELOX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

WALTHAM, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics ...

4 months ago - GlobeNewsWire

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of 202 1

5 months ago - GlobeNewsWire

A Publication titled: “ELX-02: an investigational read-through agent for the treatment of non sen se mutation-related genetic disease” has been published in the Expert Opinion on Investigational Drugs J...

5 months ago - GlobeNewsWire

WALTHAM, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics ...

5 months ago - GlobeNewsWire

Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET Company management to host a webcast and conference call to provide a b...

6 months ago - GlobeNewsWire

WALTHAM, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeuti...

7 months ago - GlobeNewsWire

WALTHAM, Mass., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutic...

7 months ago - GlobeNewsWire

WALTHAM, Mass., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutic...

8 months ago - GlobeNewsWire

Eloxx Pharmaceuticals (ELOX) CEO Greg Williams on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Enrollment in our Phase 2 clinical trial program for ELX-02 in cystic fibrosis has been resumed in Europe and Israel after being temporarily paused due to the COVID-19 pandemic

8 months ago - GlobeNewsWire

ELX-02 had previously been granted orphan medicinal product designation for the treatment of Cystic Fibrosis by the European Medicines Agency ELX-02 had previously been granted orphan medicinal product ...

8 months ago - GlobeNewsWire

WALTHAM, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutic...

8 months ago - GlobeNewsWire

Company management to host a webcast and conference call to provide a business update and review financial results at 2:00 p.m. ET Company management to host a webcast and conference call to provide a b...

8 months ago - GlobeNewsWire

ELX-02 mediates read-through of premature stop codons while maintaining the fidelity of native stop codons ELX-02 mediates read-through of premature stop codons while maintaining the fidelity of native ...

9 months ago - GlobeNewsWire

Eloxx Pharmaceuticals (NASDAQ: ELOX) shares are trading higher on Thursday. The company announced that enrollment in its Phase 2 trial for ELX-02 has resumed in Israel and Europe.

9 months ago - Benzinga

WALTHAM, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutic...

10 months ago - GlobeNewsWire

It was an overall good week for the market, but the flip to a bearish put-call ratio this morning tells us that there are plenty of volatile stocks poised for short-selling.

10 months ago - Forbes

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

These five stocks are poised to grow with the guidelines laid out to reopen the economy, as coronavirus pandemic dissipates.

Other stocks mentioned: AWR, BGCP, RMED, SHSP
11 months ago - Zacks Investment Research

Enrollment in our Phase 2 Cystic Fibrosis Trials has been paused temporarily in response to the COVID-19 pandemic

1 year ago - GlobeNewsWire

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Reiterate topline data from Phase 2 Cystic Fibrosis clinical trials for ELX-02 expected in H1 2020 Results from clinical and preclinical research to date support Company’s prioritization of Cystic F...

1 year ago - GlobeNewsWire

Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of 2020

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Eloxx.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Eloxx Pharmaceuticals, Inc. (ELOX).

1 year ago - Zacks Investment Research

Eloxx Preliminary CF Data Should Be Monitored Closely As It Advances Forward

1 year ago - Seeking Alpha

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Robert Ward on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Results of our renal impairment study for ELX-02 support the expansion of our research in the kidney beyond nephropathic cystinosis into other areas such as autosomal dominant polycystic kidney disease ...

1 year ago - GlobeNewsWire

CF Foundation and Eloxx to form joint program advisory group focused on the development of ELX-02 for cystic fibrosis

1 year ago - GlobeNewsWire

WALTHAM, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeuti...

1 year ago - GlobeNewsWire

WALTHAM, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeuti...

1 year ago - GlobeNewsWire

WALTHAM, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutic...

1 year ago - GlobeNewsWire

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Robert Ward on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

As the market played a waiting game, good news lifted several companies higher.

Other stocks mentioned: AMD, CIEN
1 year ago - The Motley Fool

Eloxx Pharmaceuticals (NASDAQ: ELOX) shares spiked higher after the company presented data for its lead investigational drug, ELX-02, at the 42nd European Cystic Fibrosis Society Conference.

1 year ago - Benzinga

Eloxx Pharmaceuticals' (ELOX) CEO Robert Ward on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About ELOX

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts.

Industry
Biotechnology
Founded
2013
CEO
Robert Ward
Employees
25
Stock Exchange
NASDAQ
Ticker Symbol
ELOX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ELOX stock is "Buy." The 12-month stock price forecast is 4.50, which is an increase of 77.17% from the latest price.

Price Target
$4.50
(77.17% upside)
Analyst Consensus: Buy